The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes

Journal of Hematotherapy and Stem Cell Research

Volumn 9, Issue 2, 2000, Pages 247-255

  Allampallam, K ^a   Dutt, D ^a   Nair, C ^a   Shetty, V ^a   Mundle, S ^a   Lisak, L ^a   Andrews, C ^a   Ahmed, B ^a   Mazzone, L ^a   Zorat, F ^a   Borok, R ^a   Muzammil, M ^a   Gundroo, A ^a   Ansaarie, I ^a   Raza, A ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IDOXURIDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANEMIA, SIDEROBLASTIC; APOPTOSIS; CELL DIVISION; CHOLESTEROL; CHROMOSOME ABERRATIONS; CYTOGENETICS; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LEUKOCYTE COUNT; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034071995     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581600319469     Document Type: Article

References (36)

1. Law MR, SG Thompson, and NJ Wald. (1994). Assessing possible hazards of reducing serum cholesterol. Br Med J 308:373-379.
2. Wannamethee G, AG Shaper, PH Whincup, and M Walker. (1995). Low serum cholesterol concentrations and mortality in middle aged British men. Br Med J 311:409-413.
3. Baptiste MS, PC Nasca, JT Doyle, RR Rothenberg, PA MacCubbin, C Mettlin, BB Metzger, and KA Carlton. (1992). Cholesterol and cancer in a population of male civil service workers. Int J Epidemiol 21:16-22.
4. Kritchevsky SB. (1992). Dietary lipids and the low blood cholesterol-cancer association. Am J Epidemiol 135: 509-520.
5. Fiorenza AU, A Branchi, A Caardena, M Molgora, A Rovellini, and D Sommariaca. (1996). Serum cholesterol levels inpatients with cancer. Relationship with nutritional status. Int J Clin Lab Res 26:37-42.
6. Markel A, and GJ Brook. (1994). Cancer and hypocholesteremia. Isr J Med Sci 30:787-793.
7. Vitols S, M Bjorkholm, G Gahrton, and C Peterson. (1985). Hypocholesteremia in malignancy due to elevated low-density lipoprotein-receptor activity in tumor cells: evidence from studies in patients with leukemia. Lancet 2(8465): 1150-1154.
8. Budd D, and H Ginsberg. (1986). Hypocholesteremia and acute myelogenous leukemia. Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 58:1361-1365.
9. Rao KN. (1995). The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis [Review]. Anticancer Res 15:309-314.
10. Bassa BV, DD Roh, ND Vaziri, MA Kirschenbaum, and VS Kamanna. (1999). Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Biophys Acta 1449:137-149.
11. Alonso DF, HG Farina, G Skilton, MR Gabri, MS De Lorenzo, and DE Gomez. (1998). Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50:83-93.
12. Hohl RJ, KA Lewis, DM Cermak, and DF Wiemer. (1998). Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphoric acids. Lipids 33:39-46.
13. Tamanoir F. (1993). Inhibitors of Ras farnesyl-transferases. Trends Biochem Sci 18:349-353.
14. Pahan K, FG Sheikh, AM Namboodiri, and I Singh. (1997). Lovastatin and phenyl acetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest 100:2671-2679.
15. Gilbert HS, H Ginsberg, R Fagerstrom, and WV Brown. (1981). Characterization of hypocholesterolemia in myeloproliferative disease: relation to disease manifestations and activity. Am J Med 71:595-602.
16. Marini A, G Carulli, A Azzara, B Grassi, and F Ambrogi. (1989). Serum cholesterol and triglycerides in hematological malignancies. Acta Haematol 81:75-79.
17. Baroni S, D Scribano, C Zuppi, L Pagano, G Leone, and B Giradina. (1996). Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol 96:24-28.
18. Raza A, S Mundle, A Iftikhar, S Gregory, B Marcus, Z Khan, S Alvi, V Shetty, S Dameron, V Wright, S Alden, J Loew, S Achott, N Ali, and H Preisler. (1995). Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 48:143-154.
19. Raza A, S Alvi, RZ Borok, L Span, A Parcharidou, D Alston, S Rifkin, E Robin, R Shah and SA Gregory. (1997). Excessive proliferation matched by excessive apoptosis in myelodysplastic syndrome: the cause-effect relationship. Leuk Lymphoma 127:111-118.
20. Heaney ML, and DW Golde. (1999). Myelodyplasia. N Engl J Med 340:1649-1660.
21. Shetty V, K Allampallam, and A Raza. (1999). Increased macrophages, high serum M-SCF and low serum cholesterol in myelodysplasia and Kawasaki disease. Br J Haematol 106:1068-1070.
22. Shetty V, S Mundle, S Alvi, M Showel, L Broady-Robinson, S Dar, R Borok, J Showel, S Gregory, S Rifkin, S Gezer, A Parcharidou, P Venugopal, R Shah, B Hernandez, M Klein, D Alston, E Robin, C Dominquez, and A Raza. (1996). Measurement of apoptosism proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20:891-900.
23. Munn DH, and N-K Cheung (1992). Pre-clinical and clinical studies of macrophage colony-stimulating factor. Seminars in Oncology 19:(4)395-407.
24. Schecter I, AM Fogelman, ME Haberland, J Seager, M Hokum, and PA Edwards. (1981). The metabolism of native and malondialdehyde-altered low density lipoproteins by human monocyte-macrophages. J Lipid Res 22:63-78.
25. Stoudemire JB, and MB Garnick. (1991). Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood 77:750-755.
26. Yoshida Y, N Anzai, and H Kawabata. (1995). Apoptosis in myelodysplasia: a paradox or paradigim. Leuk Res 12:887-891.
27. Mareni C, M Sessarego, M Montera, G Fugoazza, P Origone, E D'Amato, R Lerza, V Pistoia and GB Scarra. (1994). Expression and genomic configuration of GM-CSF, IL-3, M-CSF receptor (C-FMS), early growth response gene-1 (EGR-1) and M-CSF genes in primary myelodysplastic syndromes. Leuk Lymphoma 15:135-141.
28. Rigolin GM, A Cuneo, MG Roberti, A Bardi, and G Castoldi. (1997). Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization. Haematologica 82:25-30.
29. Janowska-Wieczorek A, AR Belch, A Jacobs, D Bowen, RA Padua, E Paietta, and ER Stanley. (1991). Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, lymphoid malignancies. Blood 77: 1796-1803.
30. Raza A, S Alvi, L Broady-Robinson, M Showel, J Cartlidge, SD Mundle, V Shetty, RZ Borok, SE Dar, HK Chopra, L Span, A Parcharidou, C Hines, S Gezer, P Venugopal, J Loew, J Showel, D Alston, B Hernandez, S Rifkin, E Robin, R Shah, and S Gregory. (1997). Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine. Exp Hematol 25:530-535.
31. Raza A, S Mundle, V Shetty, S Alvi, H Chopra, L Span, A Parcharidou, S Dar, P Venugopal, R Borok, S Gezer, J Showel, J Loew, E Robin, S Rifkin, D Alston, B Hernandez, R Shah, H Kaizer, and S Gregory. (1996). A paradigim shift in myelodysplastic syndromes. Leukemia 10:1648-1652.
32. Clark DM, and IA Lamper. (1990). Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma 2:415-418.
33. Shetty V, K Allampallam, S Hussaini, S Mundle, S Reza, J Cartlidge, I Broady-Robinson, B Li, R-W Huang, L Mazzoran, W Mahmud, E Broderick, W Townsend, S Yakoob, A Gundroo, B Mativi, H Qawi, L Lisak, H Preisler, and A Raza. (1998). Pro-and anti-apoptotic cytokines and the incidence of apoptosis in newly diagnosed cases of myelodysplastic syndromes (MDS). Proc Am Soc Hematol Blood 92:629a, abstract 2595.
34. Kitagawa M, R Kamiyama, and T Kasuga. (1993). Increase in number of bone marrow macrophages in patients with myelodysplastic syndromes. Eur J Haematol 51: 56-58.
35. Greenberg P, C Cox, MM Le Beau, P Fenaux, P Morel, G Sanz, M Sanz, T Vallespi, T Hamblin, D Oscier, K Ohyashika, K Toyama, C Aul, G Mufti, and J Bennett. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088.
36. Padua RA, BA Guinn, AI Al-Sabah, M Smith, C Taylor, T Petterssen, S Ridge, G Carter, D White, D Oscier, S Cheverts, and R West. (1998). RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasia: a 10-year follow-up. Leukemia 12:887-892.